Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURETHAL Mites dose-finding study in house dust mite allergic rhinitis
2011-000393-61Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- May 2011
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Purethal in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (5 arms), sponsored by HAL Allergy Group. Started May 2011; status: completed.
02
Drugs
Purethal
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2011-000393-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000393-61.